Sequoia Vaccines, Inc. (SQVI)
| Market Cap | 79.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.49M |
| Shares Out | 8.83M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SQVI
Sequoia Vaccines is a clinical stage pharmaceutical company developing a vaccine designed to prevent recurrent urinary tract infections (UTIs) and small molecules for treating cancers and bacterial infections. Our lead clinical candidate, SEQ-400, is a vaccine under investigation for the prevention of recurrent UTIs, which received fast track designation by the Food and Drug Administration in December 2017. We are planning a UTI observation trial in 2023 which will seek to identify and define a population of patients with culture-verified recur... [Read more]
Financial Performance
Financial StatementsNews
U.S. IPO Weekly Recap: Reinsurance And CAR T Therapies Lead A 3 IPO Week
Three IPOs and two SPACs debuted this week, while the pipeline got a boost from a flurry of initial filings. Oncology biotech CARGO Therapeutics priced at the bottom of the range to raise $281 million...
Sequoia Vaccines Begins $20 Million IPO Effort
Sequoia Vaccines, Inc. has filed for a $20 million IPO to raise funds for the development of its vaccine for urinary tract infections and treatment for ovarian cancer. The company's lead drug has show...
Vaccine developer Sequoia Vaccines files for a $20 million IPO
Sequoia Vaccines, a Phase 1 biotech developing a vaccine for recurrent UTIs and small molecules for cancers, filed on Monday with the SEC to raise up to $20 million in an initial public offering.
Sequoia Vaccines IPO Registration Document (S-1)
Sequoia Vaccines has filed to go public with an IPO on the NYSE American.